The impurity, nitrosodimethylamine (NDMA), has been identified as a risk factor in the development of certain cancers
oth the companies are recalling metformin because it may contain N-nitrosodimethylamine (NDMA) above the acceptable intake limit.
It is due to NDMA content in some lots that exceed the acceptable daily intake limit of 96ng/day
It recommends steps, including a comprehensive risk assessment strategy and other actions
Various companies across the globe have announced similar recalls for the product after the USFDA pointed out the presence of NDMA…
Lupin and Marksans Pharma recall diabetes drugs while Alembic and Aurbindo recall medicines that treat mental disorders